Insilico Medicine has made headlines by successfully launching its IPO in Hong Kong, raising approximately $293 million. The company has quickly advanced its AI-driven drug candidate, rentosertib, into phase 2 trials for idiopathic pulmonary fibrosis, showcasing the potential of AI in accelerating drug discovery.

Premier médicament entièrement conçu par une IA, le rentosertib devrait bientôt entrer en phase 3 d’essais cliniques et pourrait être commercialisé d’ici quelques années

Preliminary results from a phase 2a trial involving 71 patients suggest that a new agent, discovered and designed with artificial intelligence assistance, is safe and effective for the treatment of id...

Preliminary results from a phase 2a trial involving 71 patients suggest that a new agent, discovered and designed with artificial intelligence assistance, is safe and effective for the treatment of id...

A randomized phase 2a clinical trial of an AI-discovered drug and target combination for idiopathic pulmonary fibrosis shows safety and signs of efficacy, marking a concrete step forward in bringing…

Despite substantial progress in artificial intelligence (AI) for generative chemistry, few novel AI-discovered or AI-designed drugs have reached human clinical trials. Here we present the results of the first phase 2a multicenter, double-blind, randomized, placebo-controlled trial testing the safety and efficacy of rentosertib (formerly ISM001-055), a first-in-class AI-generated small-molecule inhibitor of TNIK, a first-in-class target in idiopathic pulmonary fibrosis (IPF) discovered using generative AI. IPF is an age-related progressive lung condition with no current therapies available that reverse the degenerative course of disease. Patients were randomized to 12 weeks of treatment with 30 mg rentosertib once daily (QD, n = 18), 30 mg rentosertib twice daily (BID, n = 18), 60 mg rentosertib QD (n = 18) or placebo (n = 17). The primary endpoint was the percentage of patients who have at least one treatment-emergent adverse event, which was similar across all treatment arms (72.2% in

Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official generic name by USAN.

Optimism for AI-powered drug discovery is rising as industry giants, startups, and even Sam Altman step up investments

Insilico Medicine has made significant strides in drug development with Rentosertib for IPF, utilizing innovative AI techniques. Promising results were published.